Abstract |
We previously reported a 60% erythroid response rate with recombinant erythropoietin + 13-cis retinoic acid + dihydroxylated vitamin D3 in 63 elderly myelodysplastic patients (median age 75 years) with unfavourable features for response to erythropoietin alone [70% transfusion-dependent, 35% refractory anaemia with ring sideroblasts/refractory anaemia with excess of blasts type 1 (RAEB1), 70% with International Prognostic Scoring System (IPSS) Intermediate-1 or -2]. This report updates that case study at a 7-year follow-up, and compared the impact on overall survival of erythroid response to known prognostic factors. The erythroid response duration (median 17 months; 22 in non- RAEB patients, with 20% patients in response after 6 years of therapy) was longer than in most studies with erythropoietin alone. Overall survival (median 55 months in non- RAEB, 15 in RAEB1 patients) was negatively affected by RAEB1 diagnosis, IPSS and WPSS intermediate scores and transfusion-dependence. In the multivariate analysis, erythroid response maintained an independent positive impact on survival, particularly in non- RAEB patients in the first 3 years from diagnosis (90% survival compared to 50% of non-responders). In conclusion, the long-term follow-up confirmed the achievement, by our combined treatment, of fairly long-lasting erythroid response in the majority of MDS patients with unfavourable prognostic features for response to erythropoietin: this translated in a survival benefit that was independent from other prognostic features.
|
Authors | Elena Crisà, Cristina Foli, Roberto Passera, Antonella Darbesio, Kimberly B Garvey, Mario Boccadoro, Dario Ferrero |
Journal | British journal of haematology
(Br J Haematol)
Vol. 158
Issue 1
Pg. 99-107
(Jul 2012)
ISSN: 1365-2141 [Electronic] England |
PMID | 22571649
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2012 Blackwell Publishing Ltd. |
Chemical References |
- Recombinant Proteins
- Erythropoietin
- Isotretinoin
- Calcitriol
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anemia, Refractory
(drug therapy)
- Calcitriol
(therapeutic use)
- Drug Administration Schedule
- Drug Therapy, Combination
- Erythropoietin
(therapeutic use)
- Female
- Humans
- Isotretinoin
(therapeutic use)
- Male
- Middle Aged
- Myelodysplastic Syndromes
(classification, drug therapy)
- Prognosis
- Recombinant Proteins
(therapeutic use)
- Survival Analysis
- Treatment Outcome
|